CD274 and neoplasm: In addition, anlotinib, a small molecule tyrosine kinase inhibitor, has demonstrated good efficacy in combination with ICI therapy in multiple tumor types; for example, a multicenter phase II clinical trial of sintilimab plus anlotinib in PD-L1-positive recurrent and metastatic advanced cervical cancer enrolled 42 patients and found an ORR of 54.8% and a disease control rate of 94.9%.